The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
May 16th 2024
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
Japan Approves Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer
Japan’s Ministry of Health, Labor, and Welfare has approved trastuzumab deruxtecan for the treatment of adult patients with HER2-positive unresectable or recurrent breast cancer after prior chemotherapy, which includes trastuzumab and a taxane.
Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022
November 21st 2022The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.
Treatment Opportunities Expand for HER2+ Breast Cancer With Brain Metastases
Suchita Pakkala, MD, discussed how treatments like tucatinib and fam-trastuzumab deruxtecan-nxki have widened the armamentarium for patients with brain metastases; the importance of enrolling these patients in clinical trials; and what future treatment sequencing might look like for this population.
Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer
Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.
Neoadjuvant Pegylated Liposomal Doxorubicin Regimen Has Promising Efficacy in HER2+ Breast Cancer
The combination of pegylated liposomal doxorubicin, cyclophosphamide, trastuzumab, and pertuzumab elicited encouraging responses with acceptable safety when given as neoadjuvant treatment in patients with HER2-positive breast cancer.
DZD1516 Demonstrates Safety, Early Activity in Heavily Pretreated Metastatic HER2+ Breast Cancer
DZD1516 monotherapy elicited early clinical activity and was found to be well tolerated in patients with HER2-positive metastatic breast cancer with or without brain metastases.
Pyrotinib Plus Trastuzumab/Docetaxel Prolongs PFS in HER2+ Metastatic Breast Cancer
The addition of pyrotinib to trastuzumab and docetaxel significantly improved progression-free survival vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer.
Zanidatamab Zovodotin Showcases Promising Safety, Activity in HER2+ Solid Cancers
Zanidatamab zovodotin was found to produce encouraging responses and to have a manageable toxicity profile when used as a monotherapy in heavily pretreated patients with HER2-positive solid cancers.
Metastatic Breast Cancer Enters a New Era of HER2 Classification
A dramatic presentation at the 2022 American Society of Clinical Oncology Annual Meeting changed treatment standards seemingly overnight for women with previously treated metastatic HER2-low breast cancer. However, fundamental questions remain.
The United Kingdom Medicines and Healthcare Products Regulatory Agency has extended the conditional marketing authorization of fam-trastuzumab deruxtecan-nxki for single-agent use in adult patients in Great Britain who have HER2-positive unresectable or metastatic breast cancer and have received 1 or more prior HER2-based regimens.
Trastuzumab Deruxtecan Shakes Up Treatment Possibilities for HER2-Low Metastatic Breast Cancer
Katherine Tkaczuk, MD, discusses practice-changing data across breast cancer subtypes that were discussed at the 2022 ASCO Annual Meeting, including data from DESTINY-Breast04 and the phase 3 PALOMA-2 trial, plus the utilization of CDK4/6 inhibitors and PARP inhibitors for select patients with breast cancer.
Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer
July 15th 2022Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.